Analysts Set Expectations for OS Therapies FY2025 Earnings

OS Therapies Inc (NYSE:OSTX) – Research analysts at Brookline Capital Management dropped their FY2025 earnings per share estimates for OS Therapies in a report issued on Wednesday, April 2nd. Brookline Capital Management analyst K. Raja now anticipates that the company will post earnings per share of ($0.31) for the year, down from their prior estimate of ($0.22). The consensus estimate for OS Therapies’ current full-year earnings is ($0.64) per share. Brookline Capital Management also issued estimates for OS Therapies’ FY2026 earnings at ($0.34) EPS.

Other equities research analysts have also recently issued research reports about the company. Maxim Group increased their price target on OS Therapies from $8.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, January 16th. Lake Street Capital assumed coverage on shares of OS Therapies in a research note on Wednesday, April 2nd. They set a “buy” rating and a $19.00 target price for the company. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $20.00 target price on shares of OS Therapies in a report on Monday, March 31st. Three investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $18.00.

OS Therapies Stock Down 9.1 %

OSTX opened at $1.40 on Monday. OS Therapies has a 12-month low of $1.33 and a 12-month high of $7.00. The business has a 50 day moving average of $1.77 and a 200-day moving average of $2.67.

Insiders Place Their Bets

In other OS Therapies news, major shareholder Shalom Auerbach sold 100,000 shares of the stock in a transaction that occurred on Friday, February 14th. The shares were sold at an average price of $2.84, for a total transaction of $284,000.00. Following the transaction, the insider now owns 2,431,211 shares in the company, valued at $6,904,639.24. This represents a 3.95 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 13.80% of the company’s stock.

Institutional Investors Weigh In On OS Therapies

A hedge fund recently raised its stake in OS Therapies stock. CM Management LLC grew its stake in shares of OS Therapies Inc (NYSE:OSTX) by 120.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 110,044 shares of the company’s stock after acquiring an additional 60,044 shares during the quarter. CM Management LLC owned about 0.51% of OS Therapies worth $471,000 as of its most recent SEC filing.

OS Therapies Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers.